SEI Investments’s Maze Therapeutics MAZE Stock Holding History

SEI Investments’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,668	Closed	-$235K	–	3348
2025 Q4	$235K	Buy	+5,668	New	+$195K	﹤0.01%	2837

Other funds holding MAZE

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SEI Investments's MAZE Position: Q1 2026 in Review

SEI Investments sold out of Maze Therapeutics (MAZE) in Q1 2026, closing a stake of 5,668 shares — an estimated $235K sold.

SEI Investments first reported a position in MAZE in Q4 2025 and held it in 1 quarter. The position peaked at $235K in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

SEI Investments reported no remaining Maze Therapeutics position as of Q1 2026 after selling out during the quarter.
SEI Investments sold 5,668 Maze Therapeutics shares in Q1 2026, an estimated $235K.
SEI Investments first reported a position in Maze Therapeutics in Q4 2025 and held it in 1 quarter.
SEI Investments's Maze Therapeutics position peaked at $235K in Q4 2025.
165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on SEI Investments's 13F filing for Q1 2026, filed 13 May 2026.